Automated radiosynthesis of mGluR5 PET tracer [¹⁸F]FPEB from aryl-chloro precursor and validation for clinical...

Area of Science:

• Radiopharmaceutical Chemistry
• Neuroimaging
• Quality Assurance

Background:

• Metabotropic glutamate receptor 5 (mGluR5) is a key target for neurological disorders.
• [¹⁸F]FPEB is a positron emission tomography (PET) radioligand for visualizing mGluR5 in the brain.
• Clinical application of novel radioligands requires stringent validation.

Purpose of the Study:

• To optimize the synthesis of [¹⁸F]FPEB for high radiochemical yield and purity.
• To validate the Good Manufacturing Practice (GMP) production of [¹⁸F]FPEB for clinical use.
• To establish comprehensive quality control measures for radiopharmaceutical batch release.

Main Methods:

• Automated one-step nucleophilic substitution radiolabeling using an aryl-chloro precursor.
• Optimization of reaction conditions for [¹⁸F]FPEB synthesis.
• Implementation of extensive quality control tests including purity, identity, stability, and safety.

Main Results:

• High radioactivity and radiochemical purity of [¹⁸F]FPEB were achieved.
• Successful validation of GMP production for clinical application.
• Established batch release criteria ensuring radiopharmaceutical quality.

Conclusions:

• The optimized synthesis and GMP validation ensure the safety, efficacy, and quality of [¹⁸F]FPEB.
• This validated radioligand is suitable for reliable clinical PET imaging of mGluR5.
• The study demonstrates a robust process for radiopharmaceutical development and clinical translation.